Winslow Evans & Crocker’s ANI Pharmaceuticals ANIP Stock Holding History

Winslow Evans & Crocker’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8	Closed	-$374	–	1121
2017 Q2	$374	Hold	8	–	–	﹤0.01%	1242
2017 Q1	$398	Hold	8	–	–	﹤0.01%	1215
2016 Q4	$486	Hold	8	–	–	﹤0.01%	1215
2016 Q3	$532	Hold	8	–	–	﹤0.01%	1251
2016 Q2	$448	Sell	8 -5	-38%	-$243	﹤0.01%	1238
2016 Q1	$438	Sell	13 -1	-7%	-$34	﹤0.01%	1240
2015 Q4	$588	Hold	14	–	–	﹤0.01%	1312
2015 Q3	$516	Hold	14	–	–	﹤0.01%	1247
2015 Q2	$810	Hold	14	–	–	﹤0.01%	1251
2015 Q1	$816	Hold	14	–	–	﹤0.01%	1223
2014 Q4	$734	Hold	14	–	–	﹤0.01%	1245
2014 Q3	$370	Buy	14 +1	+8%	+$30	﹤0.01%	1353
2014 Q2	$448	Hold	13	–	–	﹤0.01%	1260
2014 Q1	$408	Hold	13	–	–	﹤0.01%	1250
2013 Q4	$0	Buy	+13	New	+$169	﹤0.01%	1387

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Winslow Evans & Crocker's ANIP Position: Q3 2017 in Review

Winslow Evans & Crocker sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 8 shares — an estimated $374 sold.

Winslow Evans & Crocker first reported a position in ANIP in Q4 2013 and held it in 15 quarters. The position peaked at $816 in Q1 2015. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

Winslow Evans & Crocker reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Winslow Evans & Crocker sold 8 ANI Pharmaceuticals shares in Q3 2017, an estimated $374.
Winslow Evans & Crocker first reported a position in ANI Pharmaceuticals in Q4 2013 and held it in 15 quarters.
Winslow Evans & Crocker's ANI Pharmaceuticals position peaked at $816 in Q1 2015.
146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Winslow Evans & Crocker's 13F filing for Q3 2017, filed 19 Oct 2017.